BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Tamoxifen: trial readouts and FDA decisions

2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Tolmar Inc., Astellas Pharma Global Development, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma Global Development, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01-30 est.P3Tolmar Inc.NCT04906395 Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerBreast Canceractive not recruiting250
2026-12 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05780567 Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancBreast Canceractive not recruiting1946

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-06-25P3Astellas Pharma Global Development, Inc.NCT06440967 A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyHot Flashesactive not recruiting982

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.